Wang J, Gao J, Chen Q, et al. Onco Targets Ther. 2020; 13: 9333–9347. At the authors
request, we the Editor and Publisher of OncoTargets and Therapy are retracting the …

Background. Long noncoding RNAs (lncRNAs) have been shown to be involved in the
mechanism of cisplatin resistance in lung adenocarcinoma (LAD). However, the roles of …

Cisplatin (DDP)‑based chemotherapy is the most widely used therapy for non‑small cell lung
cancer (NSCLC). However, the existence of chemoresistance has become a major limitation …

Lung cancer is one of main causes of cancer mortality and 83% of lung cancer cases are
classified as non-small cell lung cancer (NSCLC). Patients with NSCLC usually have a poor …

Lung cancer is the leading cause of cancer‐associated death, and non‐small cell lung
cancer (NSCLC) accounts for 85% of all lung cancer cases. Many drugs have been used to …

Background The efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer is
limited by the acquired drug resistance. Identification the RNAs related to the cisplatin …

The aberrant expression of long non-coding RNAs is closely associated with drug resistance
in multiple types of cancer. Long intergenic non-coding RNA 00707 (LINC00707) has …

Long noncoding RNAs (lncRNAs) are critical regulators of cell biology whose alteration can
lead to the development of diseases such as cancer. The potential role of lncRNAs and their …

Adenocarcinoma is one of the most common pathological types of human lung cancer and
has the highest incidence and mortality rates worldwide. Resistance to paclitaxel (PTX), the …

Jia L, Tian Y, Chen Y, Zhang G. Onco Targets Ther. 2018; 11: 313–321. The Editor and
Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were …